{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:31:24Z","timestamp":1790119884843,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12727-3","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T15:03:59Z","timestamp":1722870239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Orhun","family":"Akdogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Ogut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Sutcuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysenur","family":"Sert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Gurler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan","family":"Akyurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"12727_CR1","doi-asserted-by":"publisher","first-page":"542657","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen J, Melero I, Fridman WH. Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:542657.","journal-title":"Front Immunol"},{"issue":"5","key":"12727_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bcp.2012.11.025","volume":"85","author":"X Wang","year":"2013","unstructured":"Wang X, Baek SJ, Eling TE. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1\/GDF15) in cancer. Biochem Pharmacol. 2013;85(5):597\u2013606.","journal-title":"Biochem Pharmacol"},{"key":"12727_CR3","doi-asserted-by":"crossref","unstructured":"Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings of the National Academy of Sciences. 2003;100(6):3410-5.","DOI":"10.1073\/pnas.0530278100"},{"issue":"7675","key":"12727_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"J-Y Hsu","year":"2017","unstructured":"Hsu J-Y, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017;550(7675):255\u20139.","journal-title":"Nature"},{"issue":"48","key":"12727_CR5","doi-asserted-by":"publisher","first-page":"49617","DOI":"10.1074\/jbc.M408796200","volume":"279","author":"K Yamaguchi","year":"2004","unstructured":"Yamaguchi K, Lee S-H, Eling TE, Baek SJ. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase\/AKT\/GSK-3\u03b2 pathway. J Biol Chem. 2004;279(48):49617\u201323.","journal-title":"J Biol Chem"},{"key":"12727_CR6","doi-asserted-by":"crossref","unstructured":"Melero Bermejo I, de Miguel MJ, Alonso G, Ramelyte E, Joerger M, Sayehli C, et al. Initial results from the phase 2A trial of visugromab (CTL-002)\u2009+\u2009nivolumab in advanced\/metastatic anti-PD1\/-L1 relapsed\/refractory solid tumors (the GDFATHER-TRIAL). American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.2501"},{"issue":"4","key":"12727_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines\u00ae insights: non\u2013small cell lung cancer, version 2.2023: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2023;21(4):340\u201350.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"12727_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.annonc.2022.01.003","volume":"33","author":"A Patel","year":"2022","unstructured":"Patel A, Goldstein D, Tannock I. Improving access to immunotherapy in low-and middle-income countries. Ann Oncol. 2022;33(4):360\u20131.","journal-title":"Ann Oncol"},{"issue":"1","key":"12727_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1878-0261.12984","volume":"16","author":"C Martin","year":"2022","unstructured":"Martin C, Cuello M, Barajas O, Recondo G, Aruachan S, Perroud H, et al. Real\u2013world evaluation of molecular testing and treatment patterns for EGFR mutations in non\u2013small cell lung cancer in Latin America. Mol Clin Oncol. 2022;16(1):1\u201310.","journal-title":"Mol Clin Oncol"},{"key":"12727_CR10","doi-asserted-by":"publisher","first-page":"107327482311897","DOI":"10.1177\/10732748231189785","volume":"30","author":"D-F Ball\u00e9n","year":"2023","unstructured":"Ball\u00e9n D-F, Carvajal-Fierro CA, Beltr\u00e1n R, Alarc\u00f3n M-L, Vallejo-Yepes C, Brug\u00e9s-Maya R. Survival outcomes of metastatic non-small cell lung cancer patients with limited access to immunotherapy and targeted therapy in a cancer center of a low-and middle-income country. Cancer Control. 2023;30:10732748231189785.","journal-title":"Cancer Control"},{"issue":"1","key":"12727_CR11","doi-asserted-by":"publisher","first-page":"8190","DOI":"10.1038\/s41598-023-35216-2","volume":"13","author":"A Gupta","year":"2023","unstructured":"Gupta A, Omeogu C, Islam JY, Joshi A, Zhang D, Braithwaite D, et al. Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database. Sci Rep. 2023;13(1):8190.","journal-title":"Sci Rep"},{"issue":"17","key":"12727_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"12727_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"12727_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"19","key":"12727_CR15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"19","key":"12727_CR16","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"key":"12727_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lungcan.2022.03.008","volume":"166","author":"A Juarez-Garcia","year":"2022","unstructured":"Juarez-Garcia A, Sharma R, Hunger M, Kayaniyil S, Penrod JR, Choua\u00efd C. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer patients: a systematic literature review. Lung Cancer. 2022;166:205\u201320.","journal-title":"Lung Cancer"},{"issue":"2","key":"12727_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"5","key":"12727_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00520-023-07771-x","volume":"31","author":"S Morita-Tanaka","year":"2023","unstructured":"Morita-Tanaka S, Miyagawa-Hayashino A, Yamada T, Matsui Y, Morimoto K, Hiranuma O, et al. Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer. Support Care Cancer. 2023;31(5):308.","journal-title":"Support Care Cancer"},{"issue":"15","key":"12727_CR20","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1158\/1078-0432.CCR-10-0705","volume":"16","author":"P Roth","year":"2010","unstructured":"Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010;16(15):3851\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"12727_CR21","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.2337\/db17-0333","volume":"66","author":"SE Lee","year":"2017","unstructured":"Lee SE, Kang SG, Choi MJ, Jung S-B, Ryu MJ, Chung HK, et al. Growth differentiation factor 15 mediates systemic glucose regulatory action of T-helper type 2 cytokines. Diabetes. 2017;66(11):2774\u201388.","journal-title":"Diabetes"},{"issue":"3\u20134","key":"12727_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/08977194.2019.1685988","volume":"37","author":"A Modi","year":"2019","unstructured":"Modi A, Dwivedi S, Roy D, Khokhar M, Purohit P, Vishnoi J, et al. Growth differentiation factor 15 and its role in carcinogenesis: an update. Growth Factors. 2019;37(3\u20134):190\u2013207.","journal-title":"Growth Factors"},{"issue":"11","key":"12727_CR23","doi-asserted-by":"publisher","first-page":"e78618","DOI":"10.1371\/journal.pone.0078618","volume":"8","author":"Z Zhou","year":"2013","unstructured":"Zhou Z, Li W, Song Y, Wang L, Zhang K, Yang J, et al. Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS ONE. 2013;8(11):e78618.","journal-title":"PLoS ONE"},{"issue":"1","key":"12727_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41467-018-03998-z","volume":"9","author":"S-B Jung","year":"2018","unstructured":"Jung S-B, Choi MJ, Ryu D, Yi H-S, Lee SE, Chang JY, et al. Reduced oxidative capacity in macrophages results in systemic insulin resistance. Nat Commun. 2018;9(1):1551.","journal-title":"Nat Commun"},{"issue":"17","key":"12727_CR25","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.4103\/0366-6999.189052","volume":"129","author":"Y-N Liu","year":"2016","unstructured":"Liu Y-N, Wang X-B, Wang T, Zhang C, Zhang K-P, Zhi X-Y, et al. Macrophage inhibitory cytokine-1 as a novel diagnostic and prognostic biomarker in stage I and II nonsmall cell lung cancer. Chin Med J. 2016;129(17):2026\u201332.","journal-title":"Chin Med J"},{"issue":"1","key":"12727_CR26","doi-asserted-by":"publisher","first-page":"17238","DOI":"10.1038\/s41598-017-17574-w","volume":"7","author":"HK Chung","year":"2017","unstructured":"Chung HK, Kim JT, Kim H-W, Kwon M, Kim SY, Shong M, et al. GDF15 deficiency exacerbates chronic alcohol-and carbon tetrachloride-induced liver injury. Sci Rep. 2017;7(1):17238.","journal-title":"Sci Rep"},{"issue":"4","key":"12727_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jcsm.12033","volume":"6","author":"L Lerner","year":"2015","unstructured":"Lerner L, Hayes TG, Tao N, Krieger B, Feng B, Wu Z, et al. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J cachexia Sarcopenia Muscle. 2015;6(4):317\u201324.","journal-title":"J cachexia Sarcopenia Muscle"},{"issue":"10","key":"12727_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23(10):1215\u20139.","journal-title":"Nat Med"},{"issue":"10","key":"12727_CR29","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican SE, Lin-Schmidt X, Chin C-N, Chavez JA, Furman JL, Armstrong AA, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23(10):1150\u20137.","journal-title":"Nat Med"},{"key":"12727_CR30","unstructured":"Jo H, Yoshida T, Horinouchi H, Yagishita S, Matsumoto Y, Shinno Y et al. Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab. Cancer Immunol Immunother. 2022:1\u201312."},{"issue":"1","key":"12727_CR31","doi-asserted-by":"publisher","first-page":"1950411","DOI":"10.1080\/2162402X.2021.1950411","volume":"10","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, et al. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology. 2021;10(1):1950411.","journal-title":"Oncoimmunology"},{"key":"12727_CR32","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13:823618.","journal-title":"Front Immunol"},{"issue":"5","key":"12727_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/resp.12789","volume":"21","author":"A Steven","year":"2016","unstructured":"Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21(5):821\u201333.","journal-title":"Respirology"},{"issue":"19","key":"12727_CR34","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"21","key":"12727_CR35","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"7","key":"12727_CR36","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"10","key":"12727_CR37","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","volume":"30","author":"E Aguilar","year":"2019","unstructured":"Aguilar E, Ricciuti B, Gainor J, Kehl K, Kravets S, Dahlberg S, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019;30(10):1653\u20139.","journal-title":"Ann Oncol"},{"issue":"2","key":"12727_CR38","doi-asserted-by":"publisher","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","volume":"4","author":"K Sehgal","year":"2021","unstructured":"Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, et al. Association of performance status with survival in patients with advanced non\u2013small cell lung cancer treated with pembrolizumab monotherapy. JAMA Netw open. 2021;4(2):e2037120\u2013e.","journal-title":"JAMA Netw open"},{"issue":"12","key":"12727_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s\u2013Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Reviews Clin Oncol. 2017;14(12):717\u201334.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"6","key":"12727_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"12727_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.","journal-title":"Front Immunol"},{"issue":"8","key":"12727_CR42","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.4161\/onci.22009","volume":"1","author":"L Senovilla","year":"2012","unstructured":"Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 2012;1(8):1323\u201343.","journal-title":"Oncoimmunology"},{"issue":"5795","key":"12727_CR43","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134.","journal-title":"Science"},{"issue":"1","key":"12727_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00432-022-04500-5","volume":"149","author":"G Hong","year":"2023","unstructured":"Hong G, Sun P, Chung C, Park D, Lee S-I, Kim N, et al. Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1\/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2023;149(1):159\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"28","key":"12727_CR45","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J, et al. Five-year overall survival for patients with advanced non\u2013small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518.","journal-title":"J Clin Oncol"},{"issue":"10","key":"12727_CR46","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411\u201320.","journal-title":"JAMA Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12727-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12727-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12727-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T15:04:37Z","timestamp":1722870277000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12727-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12727"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12727-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"1 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki. This study was approved by Gazi University Ethics Committee with the approval number E-77082166-604.01.02-763671.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"In accordance with local guidelines, the need to obtain informed consent for the use of anonymized retrospective data was waived and approved by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"954"}}